Search
for

    Glossary Gefitinib

    inhibits EGFR to treat certain non-small cell lung cancers

    Gefitinib, also known as Iressa, is a medication used to treat certain types of non-small cell lung cancer. It works by inhibiting the epidermal growth factor receptor (EGFR), which is involved in the growth and spread of cancer cells. By blocking this receptor, gefitinib can help slow down or stop the progression of the cancer.

    Research 10 of 182

    1. Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib Journal of the American Academy of Dermatology · 2006 · 57 citations
    2. Gefitinib: an adverse effects profile Expert opinion on drug safety · 2006 · 44 citations
    3. Erosive Pustular Dermatosis of the Scalp-Like Eruption due to Gefitinib: Case Report and Review of the Literature of Alopecia Associated with EGFR Inhibitors Dermatology · 2012 · 36 citations
    4. Trichoscopic Findings of Erosive Pustular Dermatosis of the Scalp Associated with Gefitinib Case Reports in Dermatology · 2017 · 21 citations
    5. Gefitinib-induced hair alterations: Figure 1 BMJ Case Reports · 2009 · 7 citations
    6. Severe Refractory Scarring Alopecia Associated With Combinational Use of Ficlatuzumab (AV-299) and Gefitinib Journal of Clinical Oncology · 2013 · 6 citations
    7. Erosive pustular dermatosis of the scalp induced by gefitinib: case and review of the literature Dermatology Online Journal · 2021 · 5 citations
    8. The Dark Side of Gefitinib: Reflectance Confocal Microscopy Applied to Hair Hyperpigmentation Skin Appendage Disorders · 2019 · 4 citations
    9. An unusual terminal hair growth on the nose tip associated with gefitinib therapy British Journal of Dermatology · 2007 · 4 citations
    10. Hair Growth After Gefitinib Treatment Clinical Oncology · 2005 · 2 citations
    All research results →

    Learn

    — no results

    Try a deeper search in learn →

    Community

    — no results

    Try a deeper search in community →